New publication using Attana Technology for interaction studies of antibodies with extracellular vesicle

The characterization of extracellular vesicles interactions is important to gain understanding of several diseases. In this paper the universities in Helsinki and Karlstad have collaborated and used state of the art technology to analyse extracellular vesicles obtained from human blood plasma. The extracellular vesicles interaction with antibodies and transmembrane proteins were detailed characterized and hence opens up for increased understanding extracellular vesicles roles in several diseases.

Extracellular vesicles (EVs) are nanosized lipid particles (50–3000nm) released from cells that can be found in various biological fluids. EVs are involved in intercellular signaling and regulating pathological and physiological processes. Among other EV subpopulations, exosomes (50–150nm) have gathered increasing attention due to their potential roles in cell communication and to their associations with various diseases. In addition to exosomes, a smaller EV subpopulation called exomere (under 50nm) has recently been identified and requires further and more extensive studies to shed light on its properties, interactions, and functions.

In this study, the teams of Prof. Riekkola at University of Helsinki and Prof. Fornstedt at Karlstad University used the Attana QCM technology to elucidate interaction characteristics such as kinetics and affinity between antibodies and recombinant transmembrane protein (ICAM-1) and exomeres (<50nm) and exosomes (50–80nm) isolated from human blood plasma. Interaction studies between EV subpopulations and affinity ligands as well as the estimation of dissociation constant is a challenging task due to multiple factors, including the estimation of available binding sites on the EV subpopulations at low EV subpopulation concentrations. Attana QCM combined with powerful algorithm (AIDA) proved to be a valuable tool for comparative estimation of biomacromolecular binding characteristics even at femto-molar (10^-15) concentrations of analytes.

Read the full publication here: https://www.sciencedirect.com/science/article/pii/S0956566322001919#bib25

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: